Treatment of triple negative breast cancer with targeted tgf-b inhibition
AssigneeMerck Patent GmbH
InventorsGeorge Locke, Isabelle Dussault
Life of this patent
Estimating the term…
Abstract
The present disclosure relates generally to methods for treating a patient diagnosed with triple negative breast cancer (TNBC), involving identifying a patient likely to respond to treatment via targeted TGF-β inhibition with an anti-TGFβ agent, and treating the subject with the anti-TGFβ agent.
Claims56
A method of treating or managing triple negative breast cancer (TNBC) in a patient, the method comprising administering an anti-TGFβ agent to a patient who has been determined to have an increased level of high mobility group AT-hook 2 (HMGA2) expression relative to a known control level, and thereby treating TNBC in the patient.
A method of achieving at least a partial response in treating or increasing survival of a triple negative breast cancer (TNBC) patient, the method comprising administering an anti-TGFβ agent to a patient who has been determined to have an increased level of high mobility group AT-hook 2 (HMGA2) expression relative to a known control level, and thereby achieving at least a partial response in treating TNBC in the patient.
A method of identifying a patient suitable for treating or managing triple negative breast cancer (TNBC) in the patient with an anti-TGFβ agent, the method comprising determining the level of high mobility group AT-hook 2 (HMGA2) in the patient, wherein an increased level of HMGA2 expression in the patient, relative to a known control level, identifies the patient as suitable for treating TNBC with said anti-TGFβ agent.
An anti-TGFβ agent for use in a method of treating or managing triple negative breast cancer (TNBC) in a patient, the method comprising administering an anti-TGFβ agent to a patient who has been determined to have an increased level of high mobility group AT-hook 2 (HMGA2) expression relative to a known control level, and thereby treating TNBC in the patient.
An anti-TGFβ agent for use in a method of achieving at least a partial response in treating or increasing survival of a triple negative breast cancer (TNBC) patient, the method comprising administering an anti-TGFβ agent to a patient who has been determined to have an increased level of high mobility group AT-hook 2 (HMGA2) expression relative to a known control level, and thereby achieving at least a partial response in treating TNBC in the patient.
An anti-TGFβ agent for use in a method of identifying a patient suitable for treating or managing triple negative breast cancer (TNBC) in the patient with an anti-TGFβ agent, the method comprising determining the level of high mobility group AT-hook 2 (HMGA2) in the patient, wherein an increased level of HMGA2 expression in the patient, relative to a known control level, identifies the patient as suitable for treating TNBC with said anti-TGFβ agent.
Dependencies are inferred from the claim text.